Recent updates concern clinical trials U3-1287 and U31287, copyrightining patritumab deruxtecan for this management of advanced female tumor. Preliminary results shown at a oncology symposium demonstrates limited therapeutic effect, although difficulties remain regarding ideal administration and patie